ORGO FY 2024 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

FY 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$482M+11.3% YoY

Gross Profit

$366M76.0% margin

Operating Income

-$1M-0.3% margin

Net Income

$861,0000.2% margin

EPS (Diluted)

$-0.01

Cash Flow

Operating Cash Flow

$14M

Free Cash Flow

$4M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$498M

Total Liabilities

$113M

Stockholders' Equity

$385M

Cash & Equivalents

$136M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$482M	$433M	+11.3%
Gross Profit	$366M	$327M	+12.1%
Operating Income	-$1M	$13M	-110.2%
Net Income	$861,000	$5M	-82.6%